| Title |
Association between the polymorphisms of urokinase plasminogen activation system and cancer risk: a meta-analysis
|
|---|---|
| Published in |
OncoTargets and therapy, September 2015
|
| DOI | 10.2147/ott.s85520 |
| Pubmed ID | |
| Authors |
Zhen Xu, Li-Li Meng, Jizong Lin, Yunbiao Ling, Shu-xian Chen, Nan Lin |
| Abstract |
The present study aimed to investigate the potential association between the urokinase plasminogen activation (uPA) system polymorphisms (rs4065, rs2227564, and rs344781) and cancer risk. An extensive search was performed to identify published case-control studies on the association between the uPA system polymorphisms and cancer risk. Odds ratios (ORs) with 95% confidence intervals (CIs) were used to evaluate the relationship between the uPA system polymorphisms and cancer risk. A total of 20 studies comprising 7,037 cancer cases and 10,094 controls were identified and included in the present meta-analysis. Overall, significantly increased cancer risk was associated with the uPA polymorphism rs4065 (T vs C: OR 1.50, 95% CI: 1.19-1.89; TT vs CC: OR 4.63, 95% CI: 3.10-6.91; dominant model: OR 1.93, 95% CI: 1.60-2.33; recessive model: OR 3.02, 95% CI: 1.26-7.25) and the uPA receptor polymorphism rs344781 (T vs C: OR 1.13, 95% CI: 1.04-1.23; TC vs CC: OR 1.26, 95% CI: 1.06-1.49; TT vs CC: OR 1.35, 95% CI: 1.13-1.63; dominant model: OR 1.29, 95% CI: 1.10-1.52). No significant association was found between the uPA polymorphism rs2227564 and cancer risk. Subgroup analysis suggests that the T allele of the rs4065 (T allele vs C allele: OR 1.50, 95% CI: 1.19-1.89) and rs344781 polymorphisms (T allele vs C allele: OR 1.13, 95% CI: 1.04-1.23) was associated with increased cancer risk in Asians. Our results suggest that the uPA polymorphism rs4065 and the uPA receptor polymorphism rs344781 are associated with increased cancer risk. |
Mendeley readers
The data shown below were compiled from readership statistics for 8 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 8 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 2 | 25% |
| Lecturer | 1 | 13% |
| Student > Postgraduate | 1 | 13% |
| Unknown | 4 | 50% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 2 | 25% |
| Unknown | 6 | 75% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 13 September 2015.
All research outputs
#22,756,649
of 25,371,288 outputs
Outputs from OncoTargets and therapy
#2,078
of 3,016 outputs
Outputs of similar age
#237,472
of 276,785 outputs
Outputs of similar age from OncoTargets and therapy
#61
of 100 outputs
Altmetric has tracked 25,371,288 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 3,016 research outputs from this source. They receive a mean Attention Score of 2.9. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 276,785 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 100 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.